These findings suggest that targeting the downstream signaling pathways shared by multiple Gi/o-GPCRs is an effective strategy for eradicating CSCs, and in turn blocking tumor development and enhancing HER2-targeted therapy. The gene discussed is ERBB2; the disease is neoplasm.